Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

<p>Abstract</p> <p>Objective</p> <p>Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes. Randomised controlled trial data suggest that exenatide is as effective as...

Full description

Bibliographic Details
Main Authors:	Tetlow Anthony P, Evans Mark, Woehl Anette, McEwan Philip
Format:	Article
Language:	English
Published:	BMC 2008-08-01
Series:	Cardiovascular Diabetology
Online Access:	http://www.cardiab.com/content/7/1/24

Similar Items

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
by: Tetlow Anthony P, et al.
Published: (2009-01-01)

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes
by: Malley Karen, et al.
Published: (2006-10-01)

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial
by: Ting-Ting Yin, et al.
Published: (2018-10-01)

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
by: Tetlow Anthony P, et al.
Published: (2009-02-01)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
by: Tarigan TJE, et al.
Published: (2021-01-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
by: Weena J. Y. Chen, et al.
Published: (2017-05-01)

Cost Effectiveness of Insulin Glargine versus Neutral Protamin Hagedorn Insulin in the Treatment of Type 2 Diabetes Patients in Turkey
by: Ilhan Satman, et al.

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Insulin glargine: A long acting insulin analog
by: Chakkarwar P, et al.
Published: (2005-01-01)

Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
by: Jacques Lepercq, et al.
Published: (2012-01-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

Insulin glargine in the treatment of type 1 and type 2 diabetes 59
by: Anthony H Barnett
Published: (2006-03-01)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
by: Kiiskinen U, et al.
Published: (2013-07-01)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
by: Xuan Du, et al.
Published: (2018-01-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-10-01)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
by: Kun-Ho Yoon, et al.
Published: (2017-12-01)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
by: Wei Liu, et al.
Published: (2018-01-01)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
by: Enrico Torre, et al.
Published: (2020-06-01)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
by: Jakobsen Marie, et al.
Published: (2012-09-01)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
by: Dippel, Franz-Werner, et al.
Published: (2010-01-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-05-01)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
by: Andersen, A., et al.
Published: (2019)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
by: Gary G. Adams, et al.
Published: (2017-08-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
by: Mark R Sommerfeld, et al.
Published: (2010-01-01)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017-04-01)

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
by: E Warren, et al.
Published: (2004-11-01)

Cost-effectiveness of intermediate or long-acting insulin versus Exenatide in type 2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications
by: Edwards KL, et al.
Published: (2006-09-01)

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-11-01)

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.
by: Xulei Tang, et al.
Published: (2012-01-01)

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
by: Lisa A Murphy, et al.
Published: (2016-11-01)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
by: Fang L. Zhou, et al.
Published: (2019-07-01)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
by: Shafie AA, et al.
Published: (2020-06-01)

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
by: Groop Leif, et al.
Published: (2009-03-01)

Cannot write session to /tmp/vufind_sessions/sess_kf09tqu774kq8qciebtugq4kng